What it is
CBL-514 is an injection given under the skin into an area of fat, in the trials so far the abdomen. The idea is local. The drug is meant to act on the fat where it is placed and not on appetite or on body weight as a whole.
Caliway's release on its second Phase 2b study says the drug triggers apoptosis in fat cells, which is the body's ordinary process for clearing cells, and names caspase 3 and the Bax to Bcl-2 ratio as the markers it moved in laboratory work. That is the company's account of the mechanism.
Why it is not a peptide
A peptide is a short chain of amino acids. The protocol Caliway filed for study CBL-0203 gives the active ingredient as curcumin and trans-resveratrol and lists the chemical registry number of each. Both are small plant compounds. Neither contains an amino acid chain.
The public copy of that protocol blacks out how much of each is in the product. So the ingredients are known and the formula is not, which matters for anyone who sees a vial for sale. We cover that in can you buy CBL-514.
What the trials found
Every study below was paid for by Caliway. Three are published in the Aesthetic Surgery Journal and one is a company release that has not been through peer review as far as we read.
| Study | Status | Design | Main result |
|---|---|---|---|
| Phase 2a, open label | Published 2022 | Three strengths compared, ultrasound | Fat volume down 24.96% from baseline at the highest strength |
| Phase 2 (CBL-0202) | Published 2025 | 76 randomised 2 to 1 against placebo, ultrasound | 69.6% lost at least 150 mL eight weeks after the last session, against none on placebo |
| Phase 2b (CBL-0204) | Published 2026 | 108 randomised 1 to 1, single blind, rating scales and MRI | 76.7% (23 of 30) improved a grade on the clinician scale against 18.9% (7 of 37). MRI fat volume down 152.9 mL, or 20.3% |
| Phase 2b (CBL-0205) | Company release, February 2025 | 173 participants at 15 sites in the US and Canada, MRI | 166.6 mL less fat against a 15.7 mL gain on placebo. 54.2% lost at least a fifth of the measured fat against 0% |
| Phase 3 (SUPREME-01) | Recruiting | Started 1 September 2026 in the US and Canada | No results. Primary completion estimated July 2027 |
| Phase 3 (SUPREME-02) | Listed as not yet recruiting | US, Canada and Australia | No results. Primary completion estimated August 2027 |
The figure going around social media, roughly 200 mL more fat lost than placebo, lines up with the company's CBL-0205 release. Treated participants lost 166.6 mL and the placebo group gained 15.7 mL, a gap of about 180 mL. In percentage terms the release gives a 22.4% reduction against a 1.8% increase.
In the same release 75.7% of treated participants improved by at least one grade on the clinician's rating scale against 27.5% on placebo.
Side effects reported so far
The CBL-0203 protocol summarises what was seen at the injection site in the first five groups of an earlier study. Warmth was reported by 81%, redness by 75%, bruising by 63%, yellow discolouration by 38%, tenderness by 31% and itching by 25%.
The company's February 2025 release says no drug-related serious adverse event occurred in the 173-person study. None of this replaces Phase 3 safety data in larger groups.
What is still not known
How long the effect lasts. The published studies measured results a few weeks after the last treatment session, and the Phase 2 paper reports its main figure at eight weeks.
How it performs when someone other than the sponsor runs the study. All four completed studies are Caliway's, and the published Phase 2b trial was single blind.
How it behaves in larger and more varied groups. The largest completed study had 173 participants. Phase 3 is where rarer problems tend to appear.
What it does to body weight. The studies were built to measure local fat volume, so they do not answer that question.
Phase 3 and the timeline
Two Phase 3 trials are registered. SUPREME-01 began on 1 September 2026 in the United States and Canada and is recruiting. Its main measure is an improvement of at least two grades on both the patient's and the clinician's rating scales. SUPREME-02 covers the United States, Canada and Australia and was still listed as not yet recruiting when we read the record.
The sponsor's estimated primary completion dates are July 2027 and August 2027. Results, a filing and a review would all have to follow before any approval. For how CBL-514 differs from the weight-loss peptides it is being compared with, see CBL-514 vs retatrutide and tirzepatide.
Questions
What is CBL-514?
An investigational injection from Caliway Biopharmaceuticals that is being studied for reducing fat under the skin at the place it is injected. It is in Phase 3 trials and has no approval that we could find.
Is CBL-514 a peptide?
No. The company describes it as a small-molecule drug, and its CBL-0203 study protocol names curcumin and trans-resveratrol as the active ingredients. Neither is a peptide.
How much fat did people lose in the trials?
In the company's second Phase 2b study, treated participants lost 166.6 mL of abdominal fat under the skin on MRI while the placebo group gained 15.7 mL. In the published Phase 2b paper the MRI figure was 152.9 mL, about a fifth of the fat in the treated area.
Does CBL-514 cause weight loss?
That is not what it has been tested for. The trials measure fat volume in one treated area and how the abdomen is rated on a visual scale. They do not report body weight as a main result.
What side effects were reported?
Mostly reactions at the injection site. An early protocol lists warmth, redness, bruising, yellow discolouration, tenderness and itching in earlier groups. The company reported no drug-related serious adverse events in its 173-person Phase 2b study.
When will the Phase 3 results come out?
The registry lists estimated primary completion in July 2027 for SUPREME-01 and August 2027 for SUPREME-02. Those are estimates set by the sponsor and they can move.
Sources
- Caliway Biopharmaceuticals, CBL-0203 protocol version 1.0, 18 October 2021, posted on ClinicalTrials.gov (NCT05234736)
- Goodman GJ and others. A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction. Aesthetic Surgery Journal, 2022. PMID 35709509
- Gold M and others. Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat, Phase II. Aesthetic Surgery Journal, 2025. PMID 40037659
- Lorenc ZP and others. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction. Aesthetic Surgery Journal, 2026. PMID 42159040
- Caliway Biopharmaceuticals. CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints, 9 February 2025
- ClinicalTrials.gov. SUPREME-01, NCT07140939
- ClinicalTrials.gov. SUPREME-02, NCT07526974